Tags · Clinical

type 2 diabetes

The population with the largest evidence base for these compounds.

65 topics 24 solved Group: Clinical

65 topics · page 1 of 3

Topic	Participants	Replies	Views	Activity
Semaglutide formulation: what is in the licensed product besides the peptide Compounds › Semaglutide SELECT trial type 2 diabetes semaglutide Semaglutide formulation: what is in the licensed product besides the peptide — setting out what I have, and where I think it stops being reliable. Comparing LEADER ( N Engl J Med , 2016) with SURMOUNT-1 ( N…	+29	35	4.4k	1h
About the Comorbidities category Clinical › Comorbidities type 2 diabetes chronic kidney disease MASH / hepatic steatosis Pinned Wiki Type 2 diabetes, hepatic steatosis, sleep apnoea, cardiovascular and renal disease. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its author…		4	16k	12h
Osteoarthritis and mechanical versus metabolic improvement Clinical › Comorbidities MASH / hepatic steatosis chronic kidney disease type 2 diabetes obstructive sleep apnoea Osteoarthritis and mechanical versus metabolic improvement Writing it up because I had to work it out twice and would rather nobody else did. Asking about a population rather than about a person. The…	+2	6	30k	12h
Molecular mass of semaglutide and why the figure differs between sources Compounds › Semaglutide SELECT trial effect size semaglutide STEP programme Molecular mass of semaglutide and why the figure differs between sources — setting out what I have, and where I think it stops being reliable. Comparing SURMOUNT-2 ( Lancet , 2023) with STEP 4 ( JAMA , 2021)…	+101	110	12k	16h
What a good consultation looks like from the other side Clinical › Prescriber conversations prior authorisation telehealth type 2 diabetes beginner friendly What a good consultation looks like from the other side — that is the question, and I have not found it answered plainly anywhere I have looked. Asking about a population rather than about a person. The…	+57	62	4.9k	22h
Type 2 diabetes and the largest part of the evidence base — does this still hold? Clinical › Comorbidities type 2 diabetes chronic kidney disease PCOS blood pressure Solved Type 2 diabetes and the largest part of the evidence base — does this still hold? I have a specific reason for asking rather than idle curiosity, and the context is below. Asking about a population rather…	+17	22	4.5k	1d
Semaglutide and gastric emptying — the mechanism behind most of the side-effect profile Compounds › Semaglutide STEP programme type 2 diabetes randomised trial SELECT trial Posting this under the heading it deserves: Semaglutide and gastric emptying — the mechanism behind most of the side-effect profile Everything below is what sits behind that. I have seen SCALE ( N Engl J Med…	+115	122	2.6k	1d
PCOS and metabolic overlap: what is and is not studied Clinical › Comorbidities chronic kidney disease MASH / hepatic steatosis obstructive sleep apnoea type 2 diabetes On the subject in the title: PCOS and metabolic overlap: what is and is not studied Working notes rather than a conclusion. Asking about a population rather than about a person. The published trials in this…		3	6.6k	1d
What to bring: records that a clinician can actually use Clinical › Prescriber conversations beginner friendly type 2 diabetes prior authorisation Solved Asking directly, because I could not find a straight answer: What to bring: records that a clinician can actually use Asking about a population rather than about a person. The published trials in this class…	+15	19	6.4k	1d
[2026 update] Second opinions: how to seek one without burning the first Clinical › Prescriber conversations prior authorisation beginner friendly type 2 diabetes Solved On the subject in the title: Second opinions: how to seek one without burning the first Working notes rather than a conclusion. General question, not a request for advice about my own care — I know the…		2	5.9k	1d
Coming back to: Preparing for an appointment: one page, three questions Clinical › Prescriber conversations telehealth beginner friendly type 2 diabetes prior authorisation Preparing for an appointment: one page, three questions — setting out what I have, and where I think it stops being reliable. General question, not a request for advice about my own care — I know the…	+51	56	1.4k	2d
Second pass at: When your prescriber and the evidence disagree Clinical › Prescriber conversations beginner friendly type 2 diabetes telehealth prior authorisation Pinned Second pass at: When your prescriber and the evidence disagree — setting out what I have, and where I think it stops being reliable. General question, not a request for advice about my own care — I know the…	+51	55	9.2k	2d
Revisiting: PCOS and metabolic overlap: what is and is not studied Clinical › Comorbidities type 2 diabetes obstructive sleep apnoea PCOS Revisiting: PCOS and metabolic overlap: what is and is not studied — setting out what I have, and where I think it stops being reliable. Asking about a population rather than about a person. The published…	+55	59	26k	2d
When your prescriber and the evidence disagree Clinical › Prescriber conversations prior authorisation telehealth type 2 diabetes When your prescriber and the evidence disagree — that is the question, and I have not found it answered plainly anywhere I have looked. General question, not a request for advice about my own care — I know…	+14	18	273	2d
Semaglutide and alcohol: what is actually documented Compounds › Semaglutide STEP programme randomised trial type 2 diabetes SELECT trial Posting this under the heading it deserves: Semaglutide and alcohol: what is actually documented Everything below is what sits behind that. I have seen STEP 8 ( JAMA , 2022) cited in support of a claim I do…	+14	18	10k	2d
Revisiting: Is there a ceiling dose beyond which semaglutide stops adding benefit? Compounds › Semaglutide type 2 diabetes randomised trial semaglutide SELECT trial Solved Revisiting: Is there a ceiling dose beyond which semaglutide stops adding benefit? — that is the question, and I have not found it answered plainly anywhere I have looked. Session topic: SURMOUNT-4 ( JAMA ,…	+5	9	30k	8d
Heart failure with preserved ejection fraction: symptom endpoints Clinical › Comorbidities type 2 diabetes obstructive sleep apnoea MASH / hepatic steatosis blood pressure Heart failure with preserved ejection fraction: symptom endpoints — setting out what I have, and where I think it stops being reliable. Asking about a population rather than about a person. The published…	+19	23	311	12d
Osteoarthritis and mechanical versus metabolic improvement — one year on Clinical › Comorbidities chronic kidney disease MASH / hepatic steatosis obstructive sleep apnoea blood pressure Under review On the subject in the title: Osteoarthritis and mechanical versus metabolic improvement — one year on Working notes rather than a conclusion. General question, not a request for advice about my own care — I…	+52	56	8.1k	15d
Coming back to: What the published dose-response for semaglutide actually looks like above 2.4 mg Compounds › Semaglutide effect size type 2 diabetes semaglutide STEP programme Solved The question in the title: What the published dose-response for semaglutide actually looks like above 2.4 mg I will give what I have already checked below so nobody repeats it. I have seen LEADER ( N Engl J…	+23	27	9.9k	1mo
Gastro-oesophageal reflux: improving or worsening? Clinical › Comorbidities PCOS obstructive sleep apnoea MASH / hepatic steatosis chronic kidney disease Solved The question in the title: Gastro-oesophageal reflux: improving or worsening? I will give what I have already checked below so nobody repeats it. Asking about a population rather than about a person. The…	+54	58	8.2k	1mo
[2026 update] What a good consultation looks like from the other side Clinical › Prescriber conversations beginner friendly type 2 diabetes telehealth The question in the title: What a good consultation looks like from the other side I will give what I have already checked below so nobody repeats it. Asking about a population rather than about a person. The…	+32	36	13k	1mo
Getting a referral rather than a refusal Clinical › Prescriber conversations telehealth beginner friendly type 2 diabetes Getting a referral rather than a refusal — setting out what I have, and where I think it stops being reliable. General question, not a request for advice about my own care — I know the difference and I would…	+8	12	32k	2mo
Is there a ceiling dose beyond which semaglutide stops adding benefit? Compounds › Semaglutide effect size type 2 diabetes SELECT trial Is there a ceiling dose beyond which semaglutide stops adding benefit? I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen SURPASS-4 ( Lancet , 2021) cited in…		2	14k	2mo
What the published dose-response for semaglutide actually looks like above 2.4 mg Compounds › Semaglutide STEP programme type 2 diabetes effect size SELECT trial Solved What the published dose-response for semaglutide actually looks like above 2.4 mg — that is the question, and I have not found it answered plainly anywhere I have looked. Session topic: SURMOUNT-4 ( JAMA ,…		2	10k	3mo
Type 2 diabetes and the largest part of the evidence base Clinical › Comorbidities chronic kidney disease obstructive sleep apnoea type 2 diabetes MASH / hepatic steatosis Posting this under the heading it deserves: Type 2 diabetes and the largest part of the evidence base Everything below is what sits behind that. General question, not a request for advice about my own care —…	+81	89	2.9k	3mo
Why semaglutide solutions can look faintly opalescent and when that matters Compounds › Semaglutide semaglutide SELECT trial randomised trial effect size Solved The question in the title: Why semaglutide solutions can look faintly opalescent and when that matters I will give what I have already checked below so nobody repeats it. Comparing LEADER ( N Engl J Med ,…	+73	79	2k	4mo
Semaglutide half-life: where the 165 to 184 hour figure comes from Compounds › Semaglutide semaglutide effect size randomised trial type 2 diabetes Wiki Semaglutide half-life: where the 165 to 184 hour figure comes from — setting out what I have, and where I think it stops being reliable. Comparing FLOW ( N Engl J Med , 2024) with STEP 4 ( JAMA , 2021) and…	+128	145	3k	4mo
The most common factual error about semaglutide on the internet — what changed since Compounds › Semaglutide effect size randomised trial SELECT trial type 2 diabetes The most common factual error about semaglutide on the internet — what changed since — setting out what I have, and where I think it stops being reliable. Comparing SURMOUNT-2 ( Lancet , 2023) with STEP 1 ( N…	+42	46	1.7k	5mo
Why semaglutide's albumin binding is the whole reason weekly dosing works Compounds › Semaglutide STEP programme SELECT trial randomised trial effect size Solved Closed Asking directly, because I could not find a straight answer: Why semaglutide's albumin binding is the whole reason weekly dosing works Session topic: SELECT ( N Engl J Med , 2023). Please read it before…		2	63k	5mo
Cardiovascular risk: reading the outcome trials as a set Clinical › Comorbidities MASH / hepatic steatosis chronic kidney disease type 2 diabetes obstructive sleep apnoea Cardiovascular risk: reading the outcome trials as a set Writing it up because I had to work it out twice and would rather nobody else did. Asking about a population rather than about a person. The published…		4	12k	5mo

Sponsored Sigma-Aldrich — certified reference materialsReference standards, analytical reagents and certified materials for method calibration. If you are validating a method, this is where the standard comes from.Reference standards →